Hollow crystalline straws of diclofenac for high-dose and carrier-free dry powder inhaler formulations

2016 ◽  
Vol 502 (1-2) ◽  
pp. 170-180 ◽  
Author(s):  
Ashkan K. Yazdi ◽  
Hugh D.C. Smyth
Keyword(s):  
Dry Powder Inhaler ◽  
High Dose ◽  
Dry Powder ◽  
Carrier Free

scholarly journals Flow and Particle Modelling of Dry Powder Inhalers: Methodologies, Recent Development and Emerging Applications

Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 189
Author(s):  
Zhanying Zheng ◽  
Sharon Shui Yee Leung ◽  
Raghvendra Gupta
Keyword(s):  
Dry Powder Inhaler ◽  
Research Direction ◽  
Particle Methods ◽  
Future Research ◽  
High Dose ◽  
Dry Powder ◽  
Multi Scale ◽  
Wide Range ◽  
Computational Fluid Dynamics Cfd ◽  
Discrete Element Methods

Dry powder inhaler (DPI) is a device used to deliver a drug in dry powder form to the lungs. A wide range of DPI products is currently available, with the choice of DPI device largely depending on the dose, dosing frequency and powder properties of formulations. Computational fluid dynamics (CFD), together with various particle motion modelling tools, such as discrete particle methods (DPM) and discrete element methods (DEM), have been increasingly used to optimise DPI design by revealing the details of flow patterns, particle trajectories, de-agglomerations and depositions within the device and the delivery paths. This review article focuses on the development of the modelling methodologies of flow and particle behaviours in DPI devices and their applications to device design in several emerging fields. Various modelling methods, including the most recent multi-scale approaches, are covered and the latest simulation studies of different devices are summarised and critically assessed. The potential and effectiveness of the modelling tools in optimising designs of emerging DPI devices are specifically discussed, such as those with the features of high-dose, pediatric patient compatibility and independency of patients’ inhalation manoeuvres. Lastly, we summarise the challenges that remain to be addressed in DPI-related fluid and particle modelling and provide our thoughts on future research direction in this field.

Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil

2018 ◽  
Vol 9 (1) ◽  
pp. 319-333 ◽  
Author(s):  
Thi-Tram Nguyen ◽  
Eun-Jin Yi ◽  
Kyu-Mok Hwang ◽  
Cheol-Hee Cho ◽  
Chun-Woong Park ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
Dry Powder ◽  
Carrier Free

scholarly journals Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine

Pharmaceutics ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 24 ◽  
Author(s):  
Imco Sibum ◽  
Paul Hagedoorn ◽  
Markus P. G. Kluitman ◽  
Martijn Kloezen ◽  
Henderik W. Frijlink ◽  
...  
Keyword(s):  
Targeted Delivery ◽  
Physical Stability ◽  
Dry Powder Inhaler ◽  
High Dose ◽  
Dry Powder ◽  
Particle Dose ◽  
Moisture Protection ◽  
The Stability ◽  
Drying Conditions ◽  
And Storage

Tuberculosis is the leading cause of death from a single infectious pathogen worldwide. Lately, the targeted delivery of antibiotics to the lungs via inhalation has received increasing interest. In a previous article, we reported on the development of a spray-dried dry powder isoniazid formulation containing an L-leucine coating. It dispersed well but had poor physical stability. In this study, we aimed to improve the stability by improving the leucine coating. To this end, we optimized the spray-drying conditions, the excipient content, and the excipient itself. Using L-leucine, the tested excipient contents (up to 5%) did not result in a stable powder. Contrary to L-leucine, the stability attained with trileucine was satisfactory. Even when exposed to 75% relative humidity, the formulation was stable for at least three months. The optimal formulation contained 3% trileucine w/w. This formulation resulted in a maximum fine particle dose of 58.00 ± 2.56 mg when a nominal dose of 80 mg was dispersed from the Cyclops® dry powder inhaler. The improved moisture protection and dispersibility obtained with trileucine are explained by its amorphous nature and a higher surface enrichment during drying. Dispersion efficiency of the device decreases at higher nominal doses.

Effect of Dosing Cup Size on the Aerosol Performance of High-Dose Carrier-Based Formulations in a Novel Dry Powder Inhaler

2019 ◽  
Vol 108 (2) ◽  
pp. 949-959
Author(s):  
Stewart Yeung ◽  
Daniela Traini ◽  
Alan Tweedie ◽  
David Lewis ◽  
Tanya Church ◽  
...  
Keyword(s):  
Dry Powder Inhaler ◽  
High Dose ◽  
Dry Powder ◽  
Aerosol Performance

The Role of Force Control Agents in High-Dose Dry Powder Inhaler Formulations

2009 ◽  
Vol 98 (8) ◽  
pp. 2770-2783 ◽  
Author(s):  
Philippe Begat ◽  
David A.V Morton ◽  
Jagdeep Shur ◽  
Paul Kippax ◽  
John N Staniforth ◽  
...  
Keyword(s):  
Force Control ◽  
Dry Powder Inhaler ◽  
High Dose ◽  
Dry Powder

scholarly journals Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler

2021 ◽  
Author(s):  
Yoen-Ju Son ◽  
Danforth P. Miller ◽  
Jeffry G. Weers
Keyword(s):  
Drug Loading ◽  
Dry Powder Inhaler ◽  
High Dose ◽  
Dose Delivery ◽  
Dry Powder ◽  
Product Density ◽  
Aerosol Performance ◽  
Drying Rates ◽  
Shell Forming ◽  
Spray Dried

This manuscript critically reviews the design and delivery of spray-dried particles for the achievement of high total lung doses (TLD) with a portable dry powder inhaler. We introduce a new metric termed the product density, which is simply the TLD of a drug divided by the volume of the receptacle it is contained within. The product density is given by the product of three terms: the packing density (the mass of powder divided by the volume of the receptacle), the drug loading (the mass of drug divided by the mass of powder), and the aerosol performance (the TLD divided by the mass of drug). This manuscript discusses strategies for maximizing each of these terms. Spray drying at low drying rates with small amounts of a shell-forming excipient (low Peclet Number) leads to formation of higher density particles with high packing densities. This enables ultrahigh TLD (>100 mg of drug) to be achieved from a single receptacle. Emptying of powder from capsules is directly proportional to the mass of powder in the receptacle, requiring an inhaled volume of about 1 L for fill masses between 40 and 50 mg and up to 3.2 L for a fill mass of 150 mg.

Sign in / Sign up

Export Citation Format

Share Document